Xintela AB (publ) (FRA:1XT)

Market Cap	23.63M +15.9%
Revenue (ttm)	267.46K -7.7%
Net Income	-3.82M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	750
Open	0.0134
Previous Close	0.0120
Day's Range	0.0134 - 0.0134
52-Week Range	0.0106 - 0.0548
Beta	n/a
RSI	45.60
Earnings Date	Feb 27, 2026

About Xintela AB

Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company’s stem cell products include XSTEM, which is in Phase I/IIa clinical development for the treatment of knee osteoarthritis, as well as in clinical study for the treatment of difficult-to-heal leg ulcers, acute respiratory distress syndrome, and other indications; and EQSTEM that is in preclinical development for the treatment of joint disease in horses. It is also developing antibody-based cancer therapies,...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2009
• Employees: 13
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 1XT

Financial Performance

In 2024, Xintela AB's revenue was 4.22 million, an increase of 5303.85% compared to the previous year's 78,000. Losses were -39.19 million, -27.54% less than in 2023.

Financial numbers in SEK